{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:44:13Z","timestamp":1764002653999},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00059-023-05205-2","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T13:02:15Z","timestamp":1694437335000},"page":"413-424","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Kardiovaskul\u00e4re Therapie bei chronischer Nierenerkrankung","Cardiovascular treatment in chronic kidney disease"],"prefix":"10.1007","volume":"48","author":[{"given":"Vincent","family":"Brandenburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turgay","family":"Saritas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan H.","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyrill","family":"Rogacev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar Henrik","family":"Heine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"issue":"7","key":"5205_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","volume":"35","author":"K Damman","year":"2014","unstructured":"Damman\u00a0K, Valente\u00a0MA, Voors\u00a0AA et al (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart\u00a0J 35(7):455\u2013469","journal-title":"Eur Heart J"},{"issue":"1","key":"5205_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ndt\/gfac254","volume":"38","author":"RT Gansevoort","year":"2023","unstructured":"Gansevoort\u00a0RT, Anders\u00a0HJ, Cozzolino\u00a0M et al (2023) What should European nephrology do with the new CKD-EPI equation? Nephrol Dial Transplant 38(1):1\u20136","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"5205_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens\u00a0PE, Levin\u00a0A (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158(11):825\u2013830","journal-title":"Ann Intern Med"},{"key":"5205_CR4","unstructured":"KDIGO (\u201eKidney Disease: Improving Global Outcomes\u201c) https:\/\/kdigo.org\/wp-content\/uploads\/2017\/02\/KDIGO_2012_CKD_GL.pdf. Zugegriffen: September 2023"},{"issue":"34","key":"5205_CR5","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren\u00a0FLJ, Mach\u00a0F, Smulders\u00a0YM, Carballo\u00a0D et\u00a0al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart\u00a0J 42(34):3227\u20133337","journal-title":"Eur Heart J"},{"issue":"1","key":"5205_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL et\u00a0al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart\u00a0J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"issue":"3","key":"5205_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner\u00a0C, Krane\u00a0V, M\u00e4rz\u00a0W et\u00a0al (2005) Atorvastatin in patients with type\u00a02 diabetes mellitus undergoing hemodialysis. N\u00a0Engl J Med 353(3):238\u2013248","journal-title":"N Engl J Med"},{"issue":"4","key":"5205_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1053\/j.ajkd.2011.05.026","volume":"58","author":"C Drechsler","year":"2011","unstructured":"Drechsler\u00a0C, Grootendorst\u00a0DC, Pilz\u00a0S et\u00a0al (2011) Wasting and sudden cardiac death in hemodialysis patients: a\u00a0post hoc analysis of 4D (Die Deutsche Diabetes Dialyse Studie). Am J Kidney Dis 58(4):599\u2013607","journal-title":"Am J Kidney Dis"},{"issue":"14","key":"5205_CR9","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstr\u00f6m","year":"2009","unstructured":"Fellstr\u00f6m\u00a0BC, Jardine\u00a0AG, Schmieder\u00a0RE et\u00a0al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N\u00a0Engl J Med 360(14):1395\u20131407","journal-title":"N Engl J Med"},{"issue":"9784","key":"5205_CR10","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent\u00a0C, Landray\u00a0MJ, Reith\u00a0C et al (2011) The effects of lowering LDL cholesterol with bsimvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a\u00a0randomised placebo-controlled trial. Lancet 377(9784):2181\u20132192","journal-title":"Lancet"},{"issue":"3","key":"5205_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M13-2453","volume":"160","author":"M Tonelli","year":"2014","unstructured":"Tonelli\u00a0M, Wanner\u00a0C (2014) Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med 160(3):182","journal-title":"Ann Intern Med"},{"key":"5205_CR12","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2215\/CJN.09121010","volume":"6","author":"W M\u00e4rz","year":"2011","unstructured":"M\u00e4rz\u00a0W, Genser\u00a0B, Drechsler\u00a0C et al (2011) Atorvastatin and low-density lipoprotein cholesterol in type\u00a02 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 6:1316\u20131325","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"5205_CR13","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","volume":"73","author":"DM Charytan","year":"2019","unstructured":"Charytan\u00a0DM, Sabatine\u00a0MS, Pedersen\u00a0TR et\u00a0al (2019) Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J\u00a0Am Coll Cardiol 73(23):2961\u20132970","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"5205_CR14","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","volume":"93","author":"PP Toth","year":"2018","unstructured":"Toth\u00a0PP, Dwyer\u00a0JP, Cannon\u00a0CP et\u00a0al (2018) Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 93(6):1397\u20131408","journal-title":"Kidney Int"},{"issue":"15","key":"5205_CR15","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen\u00a0SE, Lincoff\u00a0AM, Brennan\u00a0D et al (2023) Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N\u00a0Engl J Med 388(15):1353\u20131364","journal-title":"N Engl J Med"},{"issue":"3","key":"5205_CR16","first-page":"240","volume":"64","author":"T Saritas","year":"2023","unstructured":"Saritas\u00a0T, Floege\u00a0J (2023) Retarding progression of chronic kidney disease. Inn Med 64(3):240\u2013246","journal-title":"Inn Med"},{"issue":"3","key":"5205_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","volume":"99","author":"AK Cheung","year":"2021","unstructured":"Cheung\u00a0AK, Chang\u00a0TI, Cushman\u00a0WC et\u00a0al (2021) Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99(3):559\u2013569","journal-title":"Kidney Int"},{"issue":"22","key":"5205_CR18","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Wright\u00a0JT Jr, Williamson\u00a0JD, Whelton\u00a0PK et al (2015) A randomized trial of intensive versus standard blood-pressure control. N\u00a0Engl J Med 373(22):2103\u20132116","journal-title":"N Engl J Med"},{"issue":"1","key":"5205_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/HYPERTENSIONAHA.121.18434","volume":"79","author":"I Dasgupta","year":"2022","unstructured":"Dasgupta\u00a0I, Zoccali\u00a0C (2022) Is the KDIGO systolic blood pressure target <120\u202fmm Hg for chronic kidney disease appropriate in routine clinical practice? Hypertension 79(1):4\u201311","journal-title":"Hypertension"},{"issue":"10367","key":"5205_CR20","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa\u00a0A, Davison\u00a0B, Chioncel\u00a0O et al (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a\u00a0multinational, open-label, randomised, trial. Lancet 400(10367):1938\u20131952","journal-title":"Lancet"},{"issue":"1","key":"5205_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"TA McDonagh","year":"2022","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2022) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 24(1):4\u2013131","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"5205_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ejhf.2471","volume":"24","author":"W Mullens","year":"2022","unstructured":"Mullens\u00a0W, Martens\u00a0P, Testani\u00a0JM et al (2022) Renal effects of guideline-directed medical therapies in heart failure: a\u00a0consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 24(4):603\u2013619","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"5205_CR23","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ejhf.1697","volume":"22","author":"W Mullens","year":"2020","unstructured":"Mullens\u00a0W, Damman\u00a0K, Testani\u00a0JM et\u00a0al (2020) Evaluation of kidney function throughout the heart failure trajectory\u2014A\u00a0position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 22(4):584\u2013603","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"5205_CR24","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","volume":"99","author":"BJ Kraus","year":"2021","unstructured":"Kraus\u00a0BJ, Weir\u00a0MR, Bakris\u00a0GL et al (2021) Characterization and implications of the initial estimated glomerular filtration rate \u2018dip\u2019 upon sodium-glucose cotransporter\u20112 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int 99(3):750\u2013762","journal-title":"Kidney Int"},{"issue":"6","key":"5205_CR25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","volume":"146","author":"C Adamson","year":"2022","unstructured":"Adamson\u00a0C, Docherty\u00a0KF, Heerspink\u00a0HJL et al (2022) Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation 146(6):438\u2013449","journal-title":"Circulation"},{"issue":"15","key":"5205_CR26","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stef\u00e1nsson\u00a0BV, Correa-Rotter\u00a0R et al (2020) Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"5","key":"5205_CR27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks\u00a0G, Potpara\u00a0T, Dagres\u00a0N et al (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart\u00a0J 42(5):373\u2013498","journal-title":"Eur Heart J"},{"issue":"8","key":"5205_CR28","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.7326\/M22-0610","volume":"175","author":"T Shafi","year":"2022","unstructured":"Shafi\u00a0T, Zhu\u00a0X, Lirette\u00a0ST, Rule\u00a0AD et al (2022) Quantifying individual-level inaccuracy in glomerular filtration rate estimation: a\u00a0cross-sectional study. Ann Intern Med 175(8):1073\u20131082","journal-title":"Ann Intern Med"},{"issue":"10","key":"5205_CR29","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1681\/ASN.2009030319","volume":"20","author":"KE Chan","year":"2009","unstructured":"Chan\u00a0KE, Lazarus\u00a0JM, Thadhani\u00a0R, Hakim\u00a0RM (2009) Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J\u00a0Am Soc Nephrol 20(10):2223\u20132233","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"5205_CR30","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1093\/ndt\/gfab060","volume":"37","author":"AS De Vriese","year":"2022","unstructured":"De Vriese\u00a0AS, Heine\u00a0G (2022) Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion. Nephrol Dial Transplant 37(11):2072\u20132079","journal-title":"Nephrol Dial Transplant"},{"issue":"23","key":"5205_CR31","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","volume":"146","author":"SD Pokorney","year":"2022","unstructured":"Pokorney\u00a0SD, Chertow\u00a0GM, Al-Khalidi\u00a0HR et al (2022) Apixaban for patients with atrial fibrillation on hemodialysis: a\u00a0multicenter randomized controlled trial. Circulation 146(23):1735\u20131745","journal-title":"Circulation"},{"issue":"6","key":"5205_CR32","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1681\/ASN.2020111566","volume":"32","author":"AS De Vriese","year":"2021","unstructured":"De Vriese\u00a0AS, Caluw\u00e9\u00a0R, Van Der Meersch\u00a0H et\u00a0al (2021) Safety and efficacy of vitamin\u00a0K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a\u00a0multicenter randomized controlled trial. J\u00a0Am Soc Nephrol 32(6):1474\u20131483","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"5205_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","volume":"147","author":"H Reinecke","year":"2023","unstructured":"Reinecke\u00a0H, Engelbertz\u00a0C, Bauersachs\u00a0R et al (2023) A randomized controlled trial comparing apixaban with the vitamin\u00a0K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation 147(4):296\u2013309","journal-title":"Circulation"},{"issue":"1","key":"5205_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2021.10.023","volume":"79","author":"P Osmancik","year":"2022","unstructured":"Osmancik\u00a0P, Herman\u00a0D, Neuzil\u00a0P et al (2022) 4\u2011year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation. J\u00a0Am Coll Cardiol 79(1):1\u201314","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"5205_CR35","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/ccd.30559","volume":"101","author":"T Fink","year":"2023","unstructured":"Fink\u00a0T, Paitazoglou\u00a0C, Bergmann\u00a0MW et al (2023) Left atrial appendage closure in end-stage renal disease and hemodialysis: data from a\u00a0German multicenter registry. Catheter Cardiovasc Interv 101(3):610\u2013619","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"5205_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.7326\/M19-0087","volume":"171","author":"JT Ha","year":"2019","unstructured":"Ha\u00a0JT, Neuen\u00a0BL, Cheng\u00a0LP et al (2019) Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a\u00a0systematic review and meta-analysis. Ann Intern Med 171(3):181\u2013189","journal-title":"Ann Intern Med"},{"issue":"14","key":"5205_CR37","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet\u00a0JP, Thiele\u00a0H, Barbato\u00a0E et al (2021) 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart\u00a0J 42(14):1289\u20131367","journal-title":"Eur Heart J"},{"issue":"2","key":"5205_CR38","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/bjh.18903","volume":"202","author":"J Caruana","year":"2023","unstructured":"Caruana J, Riva N, Vella K et\u00a0al (2023) Navigating through the haemostatic paradox in kidney failure: a\u00a0practical overview. Br J Haematol 202(2):230\u2013247. https:\/\/doi.org\/10.1111\/bjh.18903","journal-title":"Br J Haematol"},{"issue":"12","key":"5205_CR39","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","volume":"381","author":"S Yasuda","year":"2019","unstructured":"Yasuda\u00a0S, Kaikita\u00a0K, Akao\u00a0M et\u00a0al (2019) Antithrombotic therapy for atrial fibrillation with stable coronary disease. N\u00a0Engl J Med 381(12):1103\u20131113","journal-title":"N Engl J Med"},{"issue":"10","key":"5205_CR40","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel\u00a0J, Collins\u00a0R, Antz\u00a0M et al (2021) 2021 European Heart Rhythm Association practical guide on the use of non-vitamin\u00a0K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 23(10):1612\u20131676","journal-title":"Europace"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-023-05205-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-023-05205-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-023-05205-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T12:04:38Z","timestamp":1695989078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-023-05205-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5205"],"URL":"https:\/\/doi.org\/10.1007\/s00059-023-05205-2","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"assertion":[{"value":"2 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>V.\u00a0Brandenburg, T.\u00a0Saritas, S.H.\u00a0Schirmer, K.\u00a0Rogacev<\/b> und <b>G.H.\u00a0Heine<\/b> geben an, dass kein Interessenkonflikt besteht.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}